X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1709) 1709
Book Review (634) 634
Publication (174) 174
Book Chapter (41) 41
Book / eBook (15) 15
Conference Proceeding (10) 10
Reference (4) 4
Dissertation (2) 2
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1513) 1513
animals (978) 978
humans (959) 959
male (595) 595
glucagon-like peptide-1 (580) 580
endocrinology & metabolism (567) 567
gastric-inhibitory polypeptide (474) 474
rats (328) 328
glucose (327) 327
diabetes (294) 294
type 2 diabetes (280) 280
female (279) 279
physiology (276) 276
mice (272) 272
insulin (263) 263
pharmacology & pharmacy (261) 261
obesity (248) 248
glucagon (244) 244
gastroenterology & hepatology (233) 233
dependent insulinotropic polypeptide (232) 232
peptides (228) 228
insulin - metabolism (226) 226
abridged index medicus (216) 216
diabetes mellitus, type 2 - drug therapy (216) 216
glp-1 (205) 205
secretion (203) 203
physiological aspects (201) 201
glucagon-like peptide 1 (183) 183
insulin secretion (183) 183
gastric inhibitory polypeptide - metabolism (174) 174
glucagon-like peptide 1 - metabolism (172) 172
gip (170) 170
blood glucose - metabolism (160) 160
dextrose (159) 159
hormones, hormone substitutes, and hormone antagonists (156) 156
adult (151) 151
biochemistry & molecular biology (151) 151
endocrine system (142) 142
research (141) 141
gastric emptying (140) 140
middle aged (140) 140
hormones (138) 138
diabetes mellitus, type 2 - metabolism (136) 136
medicine & public health (135) 135
digestive, oral, and skin physiology (133) 133
gastric inhibitory polypeptide - pharmacology (128) 128
food-intake (125) 125
glucagon-like peptide-1 receptor (124) 124
hypoglycemic agents - therapeutic use (121) 121
rodents (121) 121
incretin (116) 116
beta-cell function (114) 114
type-2 diabetes-mellitus (111) 111
internal medicine (109) 109
rats, sprague-dawley (109) 109
in vitro techniques (108) 108
glucose metabolism (106) 106
gastric emptying - drug effects (105) 105
glycemic control (104) 104
insulin - blood (104) 104
health aspects (103) 103
analysis (102) 102
bariatric surgery (102) 102
dose-response relationship, drug (102) 102
neurosciences (98) 98
release (98) 98
glucose - metabolism (97) 97
glucose-dependent insulinotropic polypeptide (95) 95
insulin resistance (95) 95
surgery (93) 93
insulin-secretion (92) 92
homeostasis (90) 90
metabolism (89) 89
peptide fragments - pharmacology (89) 89
rats, wistar (88) 88
signal transduction (88) 88
expression (87) 87
diabetes mellitus (86) 86
glucagon - metabolism (86) 86
receptor (86) 86
stomach (85) 85
diabetes mellitus, type 2 - blood (84) 84
incretins - metabolism (83) 83
article (81) 81
motility (80) 80
diabetes-mellitus (79) 79
polypeptides (79) 79
care and treatment (78) 78
7-36 amide (77) 77
gastric inhibitory polypeptide - physiology (77) 77
gastric inhibitory polypeptide - blood (76) 76
ghrelin (76) 76
electric stimulation (75) 75
glucagon-like peptide 1 - blood (75) 75
nitric oxide (75) 75
mice, inbred c57bl (74) 74
amino acid sequence (73) 73
cholecystokinin (73) 73
hypoglycemic agents - pharmacology (73) 73
review (73) 73
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (11) 11
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (2) 2
Baycrest Hospital - Stacks (1) 1
Collection Dvlpm't (Acquisitions) - Vendor file (1) 1
Providence Healthcare - Stacks (1) 1
St. Michael's Hospital - Circulation Desk (1) 1
St. Michael's Hospital - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1732) 1732
Spanish (5) 5
Japanese (2) 2
Dutch (1) 1
German (1) 1
Hungarian (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Diabetes, Obesity and Metabolism, ISSN 1462-8902, 10/2017, Volume 19, Issue 10, pp. 1436 - 1445
Aims: To investigate the pharmacodynamics, pharmacokinetics and safety of multiple ascending doses of RG7697, a dual glucose-dependent insulinotropic... 
RG7697, RO6811135 | NNC | 0090‐2746 | dual | pharmacodynamics | safety | 1 agonist | pharmacokinetics | type 2 diabetes mellitus | GLP | GIP | NNC0090-2746 | dual GIP/GLP-1 agonist | ACTIVATION | RO6811135 | RECEPTOR AGONISTS | QTC INTERVAL | RESPONSES | GLUCAGON-LIKE PEPTIDE-1 | BIOLOGY | ENDOCRINOLOGY & METABOLISM | SECRETION | GASTRIC-INHIBITORY POLYPEPTIDE | RG7697 | ASSOCIATION | Gastric Inhibitory Polypeptide - agonists | Hypoglycemic Agents - pharmacokinetics | Double-Blind Method | Humans | Middle Aged | Drugs, Investigational - pharmacokinetics | Male | Diabetes Mellitus, Type 2 - metabolism | Blood Glucose - drug effects | Dose-Response Relationship, Drug | Hypoglycemic Agents - administration & dosage | Glucagon-Like Peptide 1 - agonists | Drugs, Investigational - administration & dosage | Adult | Female | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Type 2 diabetes | Complications and side effects | Safety and security measures | Peptides | Low density lipoproteins | Glycosylated hemoglobin | Glucose | Dextrose | Appetite | Pharmacodynamics | Fasting | Polypeptides | Glucagon | Diabetes mellitus | Body weight | Diarrhea | Gastric emptying | Nausea | GIP protein | Hypoglycemia | Insulin | Immunological tolerance | Hemoglobin | Diabetes | Pharmacokinetics | Glucagon-like peptide 1 | Index Medicus
Journal Article
The Lancet, ISSN 0140-6736, 11/2018, Volume 392, Issue 10160, pp. 2180 - 2193
LY3298176 is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that is being developed for... 
MEDICINE, GENERAL & INTERNAL | SEMAGLUTIDE | PHARMACOKINETICS | INTENSIVE GLUCOSE CONTROL | WEIGHT-LOSS | PHARMACODYNAMICS | DEPENDENT INSULINOTROPIC POLYPEPTIDE | OUTCOMES | BENEFITS | BETA-CELL FUNCTION | ADIPOSE-TISSUE | Gastric Inhibitory Polypeptide - agonists | Double-Blind Method | Drug Administration Schedule | Glucagon-Like Peptides - administration & dosage | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Blood Glucose | Male | Treatment Outcome | Weight Loss - drug effects | Immunoglobulin Fc Fragments - administration & dosage | Diabetes Mellitus, Type 2 - blood | Hypoglycemic Agents - administration & dosage | Female | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptides - analogs & derivatives | Glucagon-Like Peptide-1 Receptor - agonists | Recombinant Fusion Proteins - administration & dosage | Type 2 diabetes | Clinical trials | Care and treatment | Product development | Diabetes therapy | Adenocarcinoma | Lipoproteins (low density) | Glucagon | Lung | Homeostasis | Stimulation | Body weight loss | Glucose | Receptors | Randomization | Hyperglycemia | Motivation | Vomiting | Hemoglobin | Safety | Active control | Lipoproteins (high density) | Diabetes mellitus (non-insulin dependent) | Glucagon-like peptide 1 | Appetite | Fasting | Effectiveness | Polypeptides | Diabetes mellitus | Weight loss | Diarrhea | Triglycerides | GIP protein | Nausea | Hypoglycemia | Metabolism | Patients | Cholesterol | Abdomen | Studies | Body mass | Insulin resistance | Metformin | Diabetes | Index Medicus | Abridged Index Medicus
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 10/2017, Volume 19, Issue 10, pp. 1446 - 1453
Journal Article
Journal Article
Journal Article
Molecular and Cellular Endocrinology, ISSN 0303-7207, 01/2016, Volume 420, Issue C, pp. 37 - 45
The purpose of the present study was to examine if a stable glucose-dependent insulinotropic polypeptide (GIP) agonist could exert beneficial metabolic control... 
Diabetes | Dapagliflozin | Glucose-dependent insulinotropic polypeptide (GIP) | SGLT2 inhibitor | Insulin secretion | GLP-1 | SITAGLIPTIN | polypeptide (GIP) | ISLET MORPHOLOGY | CELL BIOLOGY | OBESITY | GLUCAGON-LIKE PEPTIDE-1 | ENDOCRINOLOGY & METABOLISM | Glucose-dependent insulinotropic | IMPROVES GLUCOSE-TOLERANCE | DEGRADATION | DEPENDENT INSULINOTROPIC POLYPEPTIDE | SECRETION | Islets of Langerhans - drug effects | Diabetes Mellitus, Experimental - drug therapy | Benzhydryl Compounds - administration & dosage | Gastric Inhibitory Polypeptide - therapeutic use | Body Weight - drug effects | Male | Insulin - blood | RNA, Messenger - metabolism | Diabetes Mellitus, Experimental - blood | Body Composition - drug effects | Fasting - blood | Islets of Langerhans - metabolism | Diet, High-Fat | Glucosides - therapeutic use | Homeostasis - drug effects | Diabetes Mellitus, Experimental - metabolism | Gastric Inhibitory Polypeptide - pharmacology | Benzhydryl Compounds - therapeutic use | Sodium-Glucose Transporter 2 - genetics | Gastric Inhibitory Polypeptide - agonists | Glucosides - pharmacology | Islets of Langerhans - pathology | Sodium-Glucose Transporter 2 - metabolism | RNA, Messenger - genetics | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Gastric Inhibitory Polypeptide - administration & dosage | Bone Density - drug effects | Animals | Glucosides - administration & dosage | Benzhydryl Compounds - pharmacology | Mice | Blood Glucose - metabolism | Energy Metabolism - drug effects | Streptozocin | Blood sugar | Analysis | Body weight | Bones | Glucose tolerance tests | Density | Index Medicus
Journal Article
Journal of Endocrinology, ISSN 0022-0795, 2016, Volume 229, Issue 3, pp. 319 - 330
Ablation of glucagon receptor signaling represents a potential treatment option for type 2 diabetes (T2DM). Additionally, activation of glucose-dependent... 
Glucagon | GIP receptor agonist | Glucose homeostasis | Glucose-dependent insulinotropic polypeptide (GIP) | Insulin sensitivity | Glucagon receptor antagonist | Diet-induced obese diabetic mice | Insulin secretion | HOMEOSTASIS | GLP-1 | diet-induced obese diabetic mice | BLOOD-GLUCOSE | insulin secretion | glucose-dependent insulinotropic polypeptide (GIP) | BETA-CELL FUNCTION | glucose homeostasis | insulin sensitivity | BODY-WEIGHT | PEPTIDE-1 | ENDOCRINOLOGY & METABOLISM | glucagon | IMPROVES GLUCOSE-TOLERANCE | REPLACEMENT ANALOGS | DEPENDENT INSULINOTROPIC POLYPEPTIDE | GASTRIC-INHIBITORY POLYPEPTIDE | glucagon receptor antagonist | Cell Line | Gastric Inhibitory Polypeptide - agonists | Receptors, Glucagon - antagonists & inhibitors | Obesity - drug therapy | Insulin Resistance | Diet, High-Fat - adverse effects | Glucagon - administration & dosage | Motor Activity - drug effects | Rats | Male | Obesity - physiopathology | Gastric Inhibitory Polypeptide - administration & dosage | Glucagon - analogs & derivatives | Insulin - metabolism | Animals | Diabetes Mellitus, Type 2 - physiopathology | Cyclic AMP - biosynthesis | Mice, Obese | Obesity - etiology | Mice | Diabetes Mellitus, Type 2 - drug therapy | Gastric Inhibitory Polypeptide - analogs & derivatives | Insulin Secretion | Energy Metabolism - drug effects | Index Medicus
Journal Article
Peptides, ISSN 0196-9781, 04/2016, Volume 78, pp. 51 - 58
Selective GLP-1 secretagogues represent a novel potential therapy for type 2 diabetes mellitus. This study examined the GLP-1 secretory activity of the... 
Incretin | TGR5 | GLP-1 | Secretagogue | GIP | PROGLUCAGON | CELLS | PROTEIN | BIOCHEMISTRY & MOLECULAR BIOLOGY | RECEPTOR | INSULIN | GLP-1 SECRETION | OBESITY | ENDOCRINOLOGY & METABOLISM | PHARMACOLOGY & PHARMACY | GLUCOSE-TOLERANCE | BILE-ACIDS | Plant Extracts - chemistry | Triterpenes - pharmacology | Receptors, G-Protein-Coupled - metabolism | Zygophyllaceae - chemistry | Plant Extracts - pharmacology | Humans | Glucagon-Like Peptide 1 - biosynthesis | Incretins - metabolism | Enteroendocrine Cells - cytology | Proprotein Convertases - genetics | Glucagon-Like Peptide 1 - genetics | Glucagon-Like Peptide 1 - secretion | Incretins - genetics | Gastric Inhibitory Polypeptide - secretion | Glucagon-Like Peptide 1 - agonists | Glycosides - isolation & purification | Gastric Inhibitory Polypeptide - biosynthesis | Proglucagon - agonists | Enteroendocrine Cells - metabolism | Cell Line | Gastric Inhibitory Polypeptide - agonists | Signal Transduction | Plant Components, Aerial - chemistry | Proprotein Convertases - metabolism | Gene Expression Regulation | Proglucagon - biosynthesis | Glycosides - pharmacology | Gastric Inhibitory Polypeptide - genetics | Hypoglycemic Agents - pharmacology | Hypoglycemic Agents - isolation & purification | Incretins - agonists | Triterpenes - isolation & purification | Proglucagon - genetics | Receptors, G-Protein-Coupled - genetics | Enteroendocrine Cells - drug effects | Physiological aspects | Esters | Glucagon | Food supply | Index Medicus | Cellular | Fractionation | Partitioning | Peptides | Derivatives | Hormones | Gene expression | Secretions
Journal Article
Journal Article
American Journal of Physiology - Endocrinology and Metabolism, ISSN 0193-1849, 11/2014, Volume 307, Issue 9, pp. E830 - E837
Fat is the most potent stimulus for glucagon-like peptide-1 (GLP-1) secretion. The aims of this study were to determine whether dipeptidyl peptidase IV... 
Metabolism | Gastrointestinal hormones | Glucose | glucose | PHYSIOLOGY | FOOD-INTAKE | DPP-4 INHIBITOR | INSULIN RESPONSES | INCRETIN HORMONES | PLASMA CCK | gastrointestinal hormones | GLUCAGON-LIKE PEPTIDE-1 | ENDOCRINOLOGY & METABOLISM | ANTROPYLORODUODENAL MOTILITY | 7-36 AMIDE | metabolism | APPETITE | TYPE-2 DIABETES-MELLITUS | Dietary Fats - metabolism | Gastric Inhibitory Polypeptide - metabolism | Nitriles - pharmacology | Peptide YY - metabolism | Humans | Middle Aged | Glucagon-Like Peptide 1 - blood | Male | Insulin - blood | Dipeptidyl-Peptidase IV Inhibitors - pharmacology | Glucagon - blood | Pyrrolidines - pharmacology | Young Adult | Glucagon-Like Peptide 1 - agonists | Peptide Fragments - blood | Postprandial Period | Adult | Peptide YY - blood | Insulin Secretion | Adamantane - analogs & derivatives | Hyperglycemia - prevention & control | Adamantane - pharmacology | Gastric Inhibitory Polypeptide - agonists | Peptide Fragments - metabolism | Double-Blind Method | Glucagon-Like Peptide 1 - metabolism | Food-Drug Interactions | Appetite Regulation - drug effects | Gastric Inhibitory Polypeptide - blood | Energy Intake - drug effects | Cross-Over Studies | Hyperglycemia - metabolism | Insulin - metabolism | Hyperglycemia - blood | Adolescent | Glucagon - metabolism | Vildagliptin | Energy Metabolism - drug effects | Physiological aspects | Glucose metabolism | Protein research | Adenosine deaminase | Research | Clinical trials | Physiology | Body fat | Peptides | Bioenergetics | Index Medicus
Journal Article